# Obsidian Therapeutics, Inc. (OBX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/obsidian-therapeutics-inc/ JSON: https://steadybase.io/company/obsidian-therapeutics-inc.json Checked Nov 21, 2026. Latest filing read: Nov 12, 2026.

## Company

- Legal name: Obsidian Therapeutics, Inc.
- Ticker: OBX (Nasdaq)
- SEC CIK: 0002130606
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Cambridge, MA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Emerging growth company
- Website: obsidiantx.com
- Investor relations: https://obsidiantx.com/investors-media/
- LinkedIn: https://www.linkedin.com/company/obsidian-therapeutics
- Next earnings date: Feb 21, 2027

## Key facts

- Shares outstanding: 61,774,046 as of Nov 9, 2026 (10-Q filed Nov 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/2130606/000119312526458414/0001193125-26-458414-index.html

## Business

Obsidian Therapeutics is using its proprietary cytoDRiVE® platform to harness the power of proteins to engineer precision medicines.

Source: Company website description, https://obsidiantx.com/

## Officers and directors

- Madan Jagasia, Chief Executive Officer. LinkedIn: https://linkedin.com/in/madan-jagasia-3255754. Source: Form 4 filed Aug 5, 2026, https://www.sec.gov/Archives/edgar/data/2130606/000119312526335082/0001193125-26-335082-index.htm
- Julie B. Feder, Chief Financial Officer. LinkedIn: https://linkedin.com/in/julie-feder. Source: Form 3 filed Aug 3, 2026, https://www.sec.gov/Archives/edgar/data/2130606/000119312526330998/0001193125-26-330998-index.htm
- Parameswaran Hari, Chief Medical Officer. LinkedIn: https://linkedin.com/in/paramhari. Source: Form 3 filed Aug 3, 2026, https://www.sec.gov/Archives/edgar/data/2130606/000119312526330977/0001193125-26-330977-index.htm

## Recent 8-K events

- Nov 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2130606/000119312526458347/d20599d8k.htm
- Aug 3, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.01, Completion of acquisition or disposition of assets; Item 2.02, Results of operations and financial condition (earnings release); Item 3.02, Unregistered sales of equity securities; Item 3.03, Material modification to rights of security holders; Item 4.01, Changes in registrant's certifying accountant; Item 5.01, Changes in control of registrant; Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2130606/000119312526330810/d309963d8k.htm

## Latest filings

- 8-K filed Aug 3, 2026: https://www.sec.gov/Archives/edgar/data/2130606/000119312526330810/d309963d8k.htm
- 10-Q filed Aug 14, 2026: https://www.sec.gov/Archives/edgar/data/2130606/000119312526352381/obx-20260630.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

